1
|
Baker AG, Hartono M, Ou HL, Bistrović Popov A, Brown EL, Joseph J, Golinska M, González-Gualda E, Marcias D, Ge J, Denholm M, Morsli S, Sanghera C, Else TR, Greer HF, Vernet A, Bohndiek SE, Fruk L, Muñoz-Espín D. Indocyanine Green-based Nanoprobe for In Vivo Detection of Cellular Senescence. Angew Chem Int Ed Engl 2024:e202404885. [PMID: 38622059 DOI: 10.1002/anie.202404885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2024] [Revised: 04/12/2024] [Accepted: 04/15/2024] [Indexed: 04/17/2024]
Abstract
There is an urgent need to improve conventional cancer-treatments by preventing detrimental side effects, cancer recurrence and metastases. Recent studies have shown that presence of senescent cells in tissues treated with chemo- or radiotherapy can be used to predict the effectiveness of cancer treatment. However, although the accumulation of senescent cells is one of the hallmarks of cancer, surprisingly little progress has been made in development of strategies for their detection in vivo. To address a lack of detection tools, we developed a biocompatible, injectable organic nanoprobe (NanoJagg), which is selectively taken up by senescent cells and accumulates in the lysosomes. The NanoJagg probe is obtained by self-assembly of indocyanine green (ICG) dimers using a scalable manufacturing process and characterized by a unique spectral signature suitable for both photoacoustic tomography (PAT) and fluorescence imaging. In vitro, ex vivo and in vivo studies all indicate that NanoJaggs are a clinically translatable probe for detection of senescence and their PAT signal makes them suitable for longitudinal monitoring of the senescence burden in solid tumors after chemotherapy or radiotherapy.
Collapse
Affiliation(s)
- Andrew G Baker
- University of Cambridge, Department of Chemical Engineering and Biotechnology, UNITED KINGDOM
| | - Muhamad Hartono
- Cambridge University, Department of Chemical Engineering and Biotechnology, UNITED KINGDOM
| | - Hui-Ling Ou
- Cambridge University, Department of Oncology, UNITED KINGDOM
| | - Andrea Bistrović Popov
- University of Cambridge, Department of Chemical Engineering and Biotechnology, UNITED KINGDOM
| | - Emma L Brown
- University of Cambridge, Department of Physics, UNITED KINGDOM
| | - James Joseph
- University of Dundee, School of Science and Engineering, UNITED KINGDOM
| | - Monika Golinska
- University of Cambridge, Department of Phycics, UNITED KINGDOM
| | | | - David Marcias
- University of Cambridge, Department of Oncology, UNITED KINGDOM
| | - Jianfeng Ge
- University of Cambridge, Department of Oncology, UNITED KINGDOM
| | - Mary Denholm
- University of Cambridge, Early Cancer Institute, Department of Oncology, UNITED KINGDOM
| | - Samir Morsli
- University of Cambridge, Early Cancer Institute, Department of Oncology, UNITED KINGDOM
| | - Chandan Sanghera
- Cambridge University, Department of Chemical Engineering and Biotechnology, UNITED KINGDOM
| | - Thomas R Else
- Cambridge University, Department of Physics, UNITED KINGDOM
| | - Heather F Greer
- Cambridge University, Yusuf Hamid Department of Chemistry, UNITED KINGDOM
| | - Aude Vernet
- Cancer Research UK, Cambridge Institute, UNITED KINGDOM
| | | | - Ljiljana Fruk
- Cambridge University: University of Cambridge, Department of Chemical Engineering and Biotechnology, Philippa Fawcett Drive, t, CB3 0AS, Cambridge, UNITED KINGDOM
| | - Daniel Muñoz-Espín
- Cambridge University, Early Cancer Institute, Department of Oncology, UNITED KINGDOM
| |
Collapse
|
2
|
Haston S, Gonzalez-Gualda E, Morsli S, Ge J, Reen V, Calderwood A, Moutsopoulos I, Panousopoulos L, Deletic P, Carreno G, Guiho R, Manshaei S, Gonzalez-Meljem JM, Lim HY, Simpson DJ, Birch J, Pallikonda HA, Chandra T, Macias D, Doherty GJ, Rassl DM, Rintoul RC, Signore M, Mohorianu I, Akbar AN, Gil J, Muñoz-Espín D, Martinez-Barbera JP. Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer. Cancer Cell 2023; 41:1242-1260.e6. [PMID: 37267953 DOI: 10.1016/j.ccell.2023.05.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 03/07/2023] [Accepted: 05/05/2023] [Indexed: 06/04/2023]
Abstract
The accumulation of senescent cells in the tumor microenvironment can drive tumorigenesis in a paracrine manner through the senescence-associated secretory phenotype (SASP). Using a new p16-FDR mouse line, we show that macrophages and endothelial cells are the predominant senescent cell types in murine KRAS-driven lung tumors. Through single cell transcriptomics, we identify a population of tumor-associated macrophages that express a unique array of pro-tumorigenic SASP factors and surface proteins and are also present in normal aged lungs. Genetic or senolytic ablation of senescent cells, or macrophage depletion, result in a significant decrease in tumor burden and increased survival in KRAS-driven lung cancer models. Moreover, we reveal the presence of macrophages with senescent features in human lung pre-malignant lesions, but not in adenocarcinomas. Taken together, our results have uncovered the important role of senescent macrophages in the initiation and progression of lung cancer, highlighting potential therapeutic avenues and cancer preventative strategies.
Collapse
Affiliation(s)
- Scott Haston
- Developmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK.
| | | | - Samir Morsli
- Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Jianfeng Ge
- Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Virinder Reen
- MRC London Institute of Medical Sciences (LMS), Du Cane Road, London W12 0NN, UK; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - Alexander Calderwood
- Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK
| | - Ilias Moutsopoulos
- Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK
| | - Leonidas Panousopoulos
- Developmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK
| | - Polina Deletic
- Division of Medicine, University College London, London, UK
| | - Gabriela Carreno
- Developmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK
| | - Romain Guiho
- Developmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK
| | - Saba Manshaei
- Developmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK
| | | | - Hui Yuan Lim
- Developmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK
| | | | - Jodie Birch
- MRC London Institute of Medical Sciences (LMS), Du Cane Road, London W12 0NN, UK; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - Husayn A Pallikonda
- MRC London Institute of Medical Sciences (LMS), Du Cane Road, London W12 0NN, UK; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - Tamir Chandra
- MRC Human Generics Unit, University of Edinburgh, Edinburgh, UK
| | - David Macias
- Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Gary J Doherty
- Cambridge University Hospitals NHS Foundation Trust, Department of Oncology, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
| | - Doris M Rassl
- Royal Papworth Hospital NHS Foundation Trust. Cambridge Biomedical Campus, Cambridge CB2 0AY, UK
| | - Robert C Rintoul
- Royal Papworth Hospital NHS Foundation Trust. Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Oncology, University of Cambridge, Cambridge, UK; CRUK Cambridge Centre Thoracic Cancer Programme, Cambridge, UK
| | - Massimo Signore
- Developmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK
| | - Irina Mohorianu
- Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK
| | - Arne N Akbar
- Division of Medicine, University College London, London, UK
| | - Jesús Gil
- MRC London Institute of Medical Sciences (LMS), Du Cane Road, London W12 0NN, UK; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - Daniel Muñoz-Espín
- Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK; CRUK Cambridge Centre Thoracic Cancer Programme, Cambridge, UK.
| | - Juan Pedro Martinez-Barbera
- Developmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK.
| |
Collapse
|
3
|
Morsli S, Henriques CM, Ellis PS, Mortiboys H, Baxendale S, Loynes CA, Renshaw SA, Bellantuono I. A p21-GFP zebrafish model of senescence for rapid testing of senolytics in vivo. Aging Cell 2023; 22:e13835. [PMID: 37039087 PMCID: PMC10265157 DOI: 10.1111/acel.13835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 03/19/2023] [Accepted: 03/21/2023] [Indexed: 04/12/2023] Open
Abstract
Senescence drives the onset and severity of multiple ageing-associated diseases and frailty. As a result, there has been an increased interest in mechanistic studies and in the search for compounds targeting senescent cells, known as senolytics. Mammalian models are commonly used to test senolytics and generate functional and toxicity data at the level of organs and systems, yet this is expensive and time consuming. Zebrafish share high homology in genes associated with human ageing and disease. They can be genetically modified relatively easily. In larvae, most organs develop within 5 days of fertilisation and are transparent, which allows tracking of fluorescent cells in vivo in real time, testing drug off-target toxicity and assessment of cellular and phenotypic changes. Here, we have generated a transgenic zebrafish line that expresses green fluorescent protein (GFP) under the promoter of a key senescence marker, p21. We show an increase in p21:GFP+ cells in larvae following exposure to ionising radiation and with natural ageing. p21:GFP+ cells display other markers of senescence, including senescence-associated β-galactosidase and IL6. The observed increase in senescent cells following irradiation is associated with a reduction in the thickness of muscle fibres and mobility, two important ageing phenotypes. We also show that quercetin and dasatinib, two senolytics currently in clinical trials, reduce the number of p21:GFP+ cells, in a rapid 5-day assay. This model provides an important tool to study senescence in a living organism, allowing the rapid selection of senolytics before moving to more expensive and time-consuming mammalian systems.
Collapse
Affiliation(s)
- Samir Morsli
- The Bateson CentreUniversity of SheffieldWestern BankSheffieldS10 2THUK
- Healthy Lifespan InstituteUniversity of SheffieldWestern BankSheffieldS10 2THUK
- Department of Oncology and MetabolismUniversity of SheffieldBeech Hill RoadSheffieldS10 2RXUK
- Sheffield Institute for Translational Neuroscience, Department of NeuroscienceUniversity of Sheffield385a Glossop RoadSheffieldS10 2HQUK
- Present address:
Early Cancer InstituteUniversity of CambridgeHutchison BuildingCambridgeCB2 0XZUK
| | - Catarina M. Henriques
- The Bateson CentreUniversity of SheffieldWestern BankSheffieldS10 2THUK
- Healthy Lifespan InstituteUniversity of SheffieldWestern BankSheffieldS10 2THUK
- Department of Oncology and MetabolismUniversity of SheffieldBeech Hill RoadSheffieldS10 2RXUK
| | - Pamela S. Ellis
- The Bateson CentreUniversity of SheffieldWestern BankSheffieldS10 2THUK
- Department of Oncology and MetabolismUniversity of SheffieldBeech Hill RoadSheffieldS10 2RXUK
| | - Heather Mortiboys
- Healthy Lifespan InstituteUniversity of SheffieldWestern BankSheffieldS10 2THUK
- Sheffield Institute for Translational Neuroscience, Department of NeuroscienceUniversity of Sheffield385a Glossop RoadSheffieldS10 2HQUK
| | - Sarah Baxendale
- The Bateson CentreUniversity of SheffieldWestern BankSheffieldS10 2THUK
- Healthy Lifespan InstituteUniversity of SheffieldWestern BankSheffieldS10 2THUK
- School of BiosciencesUniversity of SheffieldSheffieldS10 2THUK
| | - Catherine A. Loynes
- The Bateson CentreUniversity of SheffieldWestern BankSheffieldS10 2THUK
- Department of Infection, Immunity and Cardiovascular DiseaseUniversity of SheffieldBeech Hill RoadSheffieldS10 2RXUK
| | - Stephen A. Renshaw
- The Bateson CentreUniversity of SheffieldWestern BankSheffieldS10 2THUK
- Healthy Lifespan InstituteUniversity of SheffieldWestern BankSheffieldS10 2THUK
- Department of Infection, Immunity and Cardiovascular DiseaseUniversity of SheffieldBeech Hill RoadSheffieldS10 2RXUK
| | - Ilaria Bellantuono
- Healthy Lifespan InstituteUniversity of SheffieldWestern BankSheffieldS10 2THUK
- Department of Oncology and MetabolismUniversity of SheffieldBeech Hill RoadSheffieldS10 2RXUK
| |
Collapse
|
4
|
Morsli S, Doherty GJ, Muñoz-Espín D. Activatable senoprobes and senolytics: Novel strategies to detect and target senescent cells. Mech Ageing Dev 2022; 202:111618. [PMID: 34990647 DOI: 10.1016/j.mad.2021.111618] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2021] [Revised: 12/21/2021] [Accepted: 12/24/2021] [Indexed: 01/10/2023]
Abstract
Pharmacologically active compounds that manipulate cellular senescence (senotherapies) have recently shown great promise in multiple pre-clinical disease models, and some of them are now being tested in clinical trials. Despite promising proof-of-principle evidence, there are known on- and off-target toxicities associated with these compounds, and therefore more refined and novel strategies to improve their efficacy and specificity for senescent cells are being developed. Preferential release of drugs and macromolecular formulations within senescent cells has been predominantly achieved by exploiting one of the most widely used biomarkers of senescence, the increase in lysosomal senescence-associated β-galactosidase (SA-β-gal) activity, a common feature of most reported senescent cell types. Galacto-conjugation is a versatile therapeutic and detection strategy to facilitate preferential targeting of senescent cells by using a variety of existing formulations, including modular systems, nanocarriers, activatable prodrugs, probes, and small molecules. We discuss the benefits and drawbacks of these specific senescence targeting tools and how the strategy of galacto-conjugation might be utilised to design more specific and sophisticated next-generation senotherapeutics, as well as theranostic agents. Finally, we discuss some innovative strategies and possible future directions for the field.
Collapse
Affiliation(s)
- Samir Morsli
- CRUK Cambridge Centre Early Detection Programme, Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK
| | - Gary J Doherty
- Department of Oncology, Box 193, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.
| | - Daniel Muñoz-Espín
- CRUK Cambridge Centre Early Detection Programme, Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.
| |
Collapse
|